Clinical trials
Terminated Cardiovascular Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
102 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 7 |
| 2010 | 5 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 12 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 102 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brigham and Women's Hospital | 3 |
| Emory University | 3 |
| Mayo Clinic | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Novartis Pharmaceuticals | 3 |
| Pfizer | 3 |
| AstraZeneca | 2 |
| Columbia University | 2 |
| Complexa, Inc. | 2 |
| David Grant U.S. Air Force Medical Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 102 |
| Heart Diseases | 16 |
| Diabetes Mellitus | 13 |
| Hypertension | 12 |
| Atherosclerosis | 11 |
| Heart Failure | 10 |
| Myocardial Infarction | 10 |
| Vascular Diseases | 10 |
| Coronary Artery Disease | 8 |
| Stroke | 7 |
Trials
Showing 1 to 25 of 102. Each trial links to its page on Pharma Observatory.
2 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.